Mouse Anti-MMP9 Recombinant Antibody (clone AB0046) (CAT#: HPAB-M0311-YC)

Figure 1 Serum concentrations of anti-MMP-9 and isotype control antibodies in mice.

Mean serum concentrations (± SD) from individual mice receiving standard TB treatment in combination with anti-MMP-9 (AB0046, red circle) or isotype control (AB5123, black circle) are depicted. Mice were sacrificed at week 2 (n = 13) and 6 (n = 13) during the dosing phase, and at week 8 (n = 13), 10 (n = 7), and 12 (n = 7) during the antibody elimination phase.

Ordonez, A. A., Pokkali, S., Kim, S., Carr, B., Klunk, M. H., Tong, L.,... & Gossage, D. L. (2018). Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas. PloS one, 13(5), e0197474.

Figure 2 shows the results of endoscopic evaluation, performed on all groups of animals on study days 10 and 14 (day of termination).

Panel A shows mean endoscopy score (+/−SEM) at days 6-14, with arrows indicating days of AB0046 (or other treatment) administration. Panel B shows mean endoscopy score (+/−SEM) at day 14 for each group, with asterisks indicating significant reduction in disease (which was observed for AB0046 and ENBREL® treatment groups at Day 14). Endoscopic score reflects the most severe lesion observed for each animal.

Figure 3 shows body weight and diarrhea results for the study.

The area under the curve (AUC) was calculated for body weight changes and diarrhea incidence by the trapezoidal rule method. Treatment with anti-MMP9 antibody (AB0046) was protective against body weight loss due to DSS-induced colitis and comparable to the effect of ENBREL® treatment. The incidence of diarrhea was similarly reduced with AB0046 and ENBREL® treatment.

Figure 4 shows a reduction of endoscopic disease by anti-MMP9 antibody (AB0047) treatment in the DSS colitis model.

Figure 5 shows the results of endoscopic evaluation, performed on all groups of animals on indicated days in the prophylactic treatment study.

Panel A shows mean endoscopy score (+/−SEM) at days 6-14, with arrows indicating days of AB0046 (or other treatment) administration. Panel B shows mean endoscopy score (+/−SEM) at day 10 for each group, with asterisks indicating significant reduction in disease (which was observed for AB0046 and ENBREL® treatment groups at Day 14). Endoscopic score reflects the most severe lesion observed for each animal.

Figure 6 shows decrease in primary tumor growth in an established colorectal tumorigenesis model (HCT116).

The left panel shows decreased change in tumor volume; the right panel shows decreased final tumor weight at day 32 after initiation of treatment (with p-values derived from Mann-Whitney test and bars representing group mean±SEM).